Acurx Pharmaceuticals LLC Total Assets
Acurx Pharmaceuticals LLC total assets. Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) holds total assets worth $10.98 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Acurx Pharmaceuticals LLC worth for the company's overall valuation and market capitalisation.
Total Assets of Acurx Pharmaceuticals LLC (2019–2025)
Total assets of Acurx Pharmaceuticals LLC from 2019 to 2025. This chart illustrates how Acurx Pharmaceuticals LLC's total assets have evolved over time, based on quarterly financial data. See ACXP stock price and chart for real-time trading data and today's change.
Acurx Pharmaceuticals LLC - Asset Composition Analysis
Acurx Pharmaceuticals LLC Total Assets Breakdown (December 2025)
Acurx Pharmaceuticals LLC total assets breakdown as of December 2025. Acurx Pharmaceuticals LLC's total assets of $10.98 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.3% |
| Accounts Receivable | $48.42K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ACXP working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acurx Pharmaceuticals LLC's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 98.3% of total assets in 2025, up from 98.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Acurx Pharmaceuticals LLC Competitors by Total Assets
Key competitors of Acurx Pharmaceuticals LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Acurx Pharmaceuticals LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.88 | 2.38 | 21.04 |
| Quick Ratio | 3.88 | 2.38 | 21.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.15 Million | $3.57 Million | $14.28 Million |
Acurx Pharmaceuticals LLC - Advanced Valuation Insights
This section examines the relationship between Acurx Pharmaceuticals LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | 99.3% |
| Total Assets | $7.69 Million |
| Market Capitalization | $4.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Acurx Pharmaceuticals LLC's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Acurx Pharmaceuticals LLC's assets grew by 99.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual total assets of Acurx Pharmaceuticals LLC from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.69 Million | +99.32% |
| 2024-12-31 | $3.86 Million | -49.96% |
| 2023-12-31 | $7.71 Million | -17.78% |
| 2022-12-31 | $9.38 Million | -29.25% |
| 2021-12-31 | $13.25 Million | +311.11% |
| 2020-12-31 | $3.22 Million | +27.36% |
| 2019-12-31 | $2.53 Million | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more